What are the AUA treatment guidelines for symptomatic, metastatic castration-resistant prostate cancer (CRPC) with good performance status and no prior docetaxel chemotherapy?

Updated: Jul 31, 2017
  • Author: Bagi RP Jana, MD; more...
  • Print


Recommendations are as follows:

  • Docetaxel

  • Abiraterone plus prednisone, enzalutamide, or docetaxel

  • Ketoconazole plus steroid, mitoxantrone, or radionuclide therapy for patients who do not want or cannot have one of the standard therapies

  • Radium-223 to patients with symptoms from bony metastases and without known visceral disease

  • Treatment with either estramustine or sipuleucel-T should not be offered

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!